CTRV News and Press, ContraVir Pharmaceuticals Inc. From 04/25/19

EDISON, N.J., April 25, 2019 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (“ContraVir,” the “Company,” “we,” “our” or “us”) (NASDAQ:CTRV), a biopharmaceutical company focused on the development of therapeutic drugs...

Market Assessment ContraVir Pharmaceuticals ( CTRV ) is a small-cap ($3.44M) clinical-stage biopharma developing innovative therapeutics for chronic liver diseases, hepatocellular carcinoma ((HCC)), viral liver diseases (HBV, HCV and HDV) and NASH, with high unmet medical needs. Its drug...

ContraVir Pharmaceuticals (NASDAQ: CTRV ) slips  2%  after hours in reaction to its planned offering of 9,615,384 Class A Units and 2,500 Class B Units. More news on: ContraVir Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more ...

EDISON, N.J., April 11, 2019 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic viral infection, today...

Chimerix (NASDAQ: CMRX ) discloses that licensee Contravir Pharmaceuticals (NASDAQ: CTRV ) will terminate its license agreement for antiviral candidate CMX157 effective June 1 after deciding to stop development. More news on: Chimerix, Inc., ContraVir Pharmaceuticals, Inc., Healthcare st...

EDISON, N.J., March 04, 2019 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic ...

ContraVir Pharmaceuticals (NASDAQ: CTRV ) has filed a prospectus for a public offering of Class A and Class B Units. More news on: ContraVir Pharmaceuticals, Inc., Healthcare stocks news, Read more ...

EDISON, N.J., Nov. 06, 2018 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of therapeutic drugs for the treatment of liver disease arising from chronic viral infection and non-alcoholic steatohe...

Experienced Industry Executives Provide Company with Broad Life Science Industry Expertise Including Drug Development and Commercialization CARLSBAD, Calif., Oct. 30, 2018 (GLOBE NEWSWIRE) -- Leading BioSciences, a drug development company focused on improving human health through the...

EDISON, N.J., Oct. 30, 2018 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of therapeutic drugs for the treatment of hepatitis B virus (“HBV”), today announced that it has complete...